The US Food and Drug Administration has cleared a novel COVID-19 vaccine called mRNA-1273 to begin phase 2 trials with 600 participants.

The vaccine started human phase 1 trials in March 2020 and was tested for six weeks in 45 healthy adults ages 18-55 years.

Dr. Andrew Mugira shares more highlights in the IDI COVID-19 Science Summary